The developers of an artificial intelligence-based diagnostic tool for musculoskeletal and neurological disorders need to change its marketing or stop distributing the product until it is approved under a PMA, a 10 February warning letter posted to the US Food and Drug Administration’s website this week states.
The Exer Scan from Denver-based Exer Labs Inc. is a mobile app that gathers real-time motion data to help clinicians...